Next generation of DataOps, provided by Datalytyx, now available through Snowflake Partner Connect Program!
5.6.2020 12:10:00 EEST | Business Wire | Press release
Datalytyx today announced an expanded partnership with Snowflake, the Cloud Data Platform, that enables the next generation Datalytyx DataOps for Snowflake platform to be deployed for a 2 week trial on Snowflake. Customers can orchestrate the ingestion of data from many on-premise and cloud platforms via 3rd party data tools, model data easily, automatically test those models as part of their pipelines, launch AI/ML models and enable the consumption of data to deliver immediate stakeholder value.
As a great example, in the midst of the Coronavirus pandemic, BOC, the UK market-leading gas supply company for delivery of healthcare oxygen, has faced unprecedented demand, from equipping Nightingale hospitals to delivering O2 cylinders in homes. Datalytyx have deployed their DataOps for Snowflake platform to help BOC manage their cylinder stock and logistics data, for all types of gases, to increase production efficiency and provide best-in-class customer service.
“Datalytyx said they could get their DataOps Platform in and working within three weeks, and they did. What’s more, the capability it’s bringing us, to set up, monitor and amend data feeds simply and rapidly, is really quite transformational.”
David Galloway, Strategy and Business Insight Manager for BOC
And at wejo, the connected car company, they have been innovating in connected car data to create ground-breaking products and services that revolutionise the way people travel. By generating insights to harness the value of that data, they enable smarter, safer and more sustainable journeys for all. Datalytyx have deployed their DataOps for Snowflake platform to orchestrate multiple Snowflake cloud data platform tenants accessing a single primary Snowflake datastore using Snowflake Secure Data Sharing, plus Jupyter Notebooks and Tableau Online at the front end of each tenant.
"Snowflake and Datalytyx DataOps are at the heart of these new ideas for secure data sharing with our customers, and some of the new geospatial features from Snowflake will enhance this further. An initial proof of concept demonstrated how the Datalytyx thinking would complement our own, to deliver ADEPT Preview faster and more confidently than we could by ourselves. Their DataOps based approach could deliver repeatable, consistent, disposable and secure data environments for our customers in ¼ of the time."
Steve Pimblett, CIO and CDO of wejo
Snowflake Chief Technical Evangelist, Kent Graziano said “Organizations today require business agility without any sacrifices to data governance and security. Datalytyx Data Ops for Snowflake can enable customers to leverage the elastic scaling and single, integrated, secured platform benefits of Snowflake, enhanced by the CI/CD automation, audit, and governance features of this new product from Datalytyx to help achieve that business agility.”
“Snowflake delivers unique value to our customers.” said Justin Mullen, CEO of Datalytyx. “We have been working on the philosophy of DataOps and #TrueDataOps with industry pioneers for the last 12 months. #TrueDataOps has only become possible because of a number of significant and critical advancements that today are unique to Snowflake’s Cloud Data Platform. “Our DataOps for Snowflake platform enables organisations to focus on value-led development of pipelines (e.g. reduce fraud, improve customer experience, increase uptake, identify opportunities, etc.) to produce analytical processes that support and enable the achievement of that value.”
About Datalytyx
Datalytyx enables organisations to deliver better data, faster, to their customers. In 2018 Datalytyx started looking at how we could reduce the time to insight, and accelerate the time to value for our customers. In 2019 we have been developing our technologies around the emerging discipline of DataOps (with a clear focus on the true principles of DevOps) and extracting value from volume in IoT data. And in 2020 we publicly shared our DataOps Philosophy (#TrueDataOps) and released our DataOps for Snowflake platform supported by our patent-pending IoT Data Compression algorithm, Datalytyx Gallium.
Datalytyx makes it easier for you to do cool, critical, valuable and smart things with data. We provide the technology, skills, and resources to deliver better data faster. Reduced risk, fewer headaches and lower overall cost.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200605005054/en/
Contact information
Justin Mullen
+44 7710 482520
justin.mullen@datalytyx.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom